Stonepine Capital Management LLC Grows Position in Coherus Oncology, Inc. $CHRS

Key Points

• Stonepine Capital Management LLC significantly increased its stake in Coherus Oncology by 148.2%, now holding 620,588 shares valued at approximately $501,000.
• Several institutional investors have also raised their positions in Coherus Oncology, with 72.82% of the company currently owned by hedge funds and institutional investors.
• Analyst ratings are mixed, with HC Wainwright maintaining a "buy" rating and a target price of $7.00, while Wall Street Zen downgraded the stock from "hold" to "sell."

Stonepine Capital Management LLC boosted its stake in shares of Coherus Oncology, Inc. (NASDAQ:CHRS - Free Report) by 148.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 620,588 shares of the biotechnology company's stock after purchasing an additional 370,588 shares during the period. Stonepine Capital Management LLC owned about 0.54% of Coherus Oncology worth $501,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its position in Coherus Oncology by 32.4% during the fourth quarter. Wells Fargo & Company MN now owns 61,830 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 15,137 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Coherus Oncology by 97.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company's stock worth $43,000 after buying an additional 15,214 shares in the last quarter. CWM LLC increased its stake in Coherus Oncology by 96.6% in the 1st quarter. CWM LLC now owns 49,793 shares of the biotechnology company's stock worth $40,000 after buying an additional 24,468 shares in the last quarter. Bank of Montreal Can purchased a new stake in Coherus Oncology in the 4th quarter worth $34,000. Finally, Cerity Partners LLC increased its stake in Coherus Oncology by 84.0% in the 1st quarter. Cerity Partners LLC now owns 54,676 shares of the biotechnology company's stock worth $44,000 after buying an additional 24,953 shares in the last quarter. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Coherus Oncology in a research note on Tuesday, April 29th. Wall Street Zen lowered Coherus Oncology from a "hold" rating to a "sell" rating in a research note on Tuesday, May 20th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Coherus Oncology currently has an average rating of "Moderate Buy" and an average target price of $4.68.

Coherus Oncology Trading Up 8.8%

Shares of Coherus Oncology stock opened at $1.23 on Friday. The firm has a market cap of $142.96 million, a price-to-earnings ratio of 0.79 and a beta of 0.89. The business has a 50-day moving average price of $0.89 and a 200-day moving average price of $0.93. The company has a quick ratio of 1.43, a current ratio of 1.44 and a debt-to-equity ratio of 0.31. Coherus Oncology, Inc. has a twelve month low of $0.6603 and a twelve month high of $2.43.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.